Michael R. Hayden Buys 5,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Michael R. Hayden purchased 5,000 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $36.22 per share, with a total value of $181,100.00. Following the purchase, the director now directly owns 35,219 shares in the company, valued at $1,275,632.18. This represents a 16.55 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ionis Pharmaceuticals Price Performance

Shares of Ionis Pharmaceuticals stock opened at $35.91 on Friday. The stock has a 50 day moving average price of $37.21 and a 200-day moving average price of $42.16. Ionis Pharmaceuticals, Inc. has a one year low of $33.33 and a one year high of $54.44. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of -14.72 and a beta of 0.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IONS. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, September 26th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Guggenheim dropped their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Finally, StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock worth $106,922,000 after purchasing an additional 183,814 shares during the period. Great Point Partners LLC purchased a new position in shares of Ionis Pharmaceuticals during the second quarter valued at approximately $15,728,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after buying an additional 114,914 shares during the period. DRW Securities LLC bought a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $2,429,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Ionis Pharmaceuticals by 13.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company’s stock valued at $26,070,000 after acquiring an additional 77,909 shares during the period. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.